Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.7.10.2 extracted from

  • Cortes, J.; Jabbour, E.; Kantarjian, H.; Yin, C.C.; Shan, J.; Obrien, S.; Garcia-Manero, G.; Giles, F.; Breeden, M.; Reeves, N.; Wierda, W.G.; Jones, D.
    Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors (2007), Blood, 110, 4005-4011.
    View publication on PubMed

Application

Application Comment Organism
drug development the enzyme is a target for development and evaluation of tyrosine kinase inhibitors Homo sapiens

Protein Variants

Protein Variants Comment Organism
A433T naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
D276G naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
E255K naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
E355A naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
E355G naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
E453K naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
E459G naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
E459K naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
E459Q naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
F311I naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
F317L naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
F359C naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
F359V naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
F486S naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
G250E naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
H396P naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
H396R naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
K247L naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
L248V naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
L298V naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
L364I naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
M244V naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
M351T naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
Q252H naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
T315I naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
T495R naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
V299L naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
Y253F naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens
Y253H naturally occuring mutation in kinase ABL1 of chronic myeloid leukemia patients Homo sapiens

Inhibitors

Inhibitors Comment Organism Structure
bosutinib i.e. SKI-606, a dual Src/Abl inhibitor Homo sapiens
dasatinib response of enzymes with BCR-ABL kinase domain in in vivo study are similar for patients with different mutations, except for T315I, which is more resistant Homo sapiens
imatinib response of enzymes with BCR-ABL kinase domain in in vivo study are similar for patients with different mutations, except for T315I, which is more resistant Homo sapiens
additional information development and evaluation of tyrosine kinase inhibitors Homo sapiens
nilotinib response of enzymes with BCR-ABL kinase domain in in vivo study are similar for patients with different mutations, except for T315I, which is more resistant Homo sapiens

Natural Substrates/ Products (Substrates)

Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
additional information Homo sapiens dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors, overview ?
-
?

Organism

Organism UniProt Comment Textmining
Homo sapiens P00519 ABL1; patients with chronic myeloid leukemia
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
additional information dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors, overview Homo sapiens ?
-
?

Synonyms

Synonyms Comment Organism
ABL1
-
Homo sapiens
Bcr-Abl kinase
-
Homo sapiens